Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1NET 1Genitourinary 1Endocrine 1

Conditions

Neuroendocrine Tumors 1Neoplasm Metastasis 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Everolimus 5pembrolizumab 2cabozantinib 2Trastuzumab 2Nivolumab 2vatalanib 1tumor necrosis factor-alpha, CNGRC fusion protein, human 1tipifarnib 1temsirolimus 1spartalizumab 1romidepsin 1regorafenib 1pentetreotide 1guadecitabine 1fostamatinib 1exemestane 1entrectinib 1entinostat 1belzutifan 1avelumab 1alectinib 1Vinorelbine 1Sirolimus 1Rosiglitazone 1Ritonavir 1Radiotherapy 1Quality of Life 1Patient Reported Outcome Measures 1Oxaliplatin 1Nephrectomy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Renal Cell × LY2584702 × Endocrine × Clear all
NCT01115803 2019-02-05

A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors

Eli Lilly and Company

Phase 1 Terminated
29 enrolled 19 charts
EndocrineGenitourinaryNETThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Neoplasm Metastasis, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡